# Pfizer, AstraZeneca, Merck, and others are capitalizing on exemptions and direct consumer strategies to mitigate tariff impacts.

*biotech · news · 2026-05-04 · Devdiscourse*

## Key points

- Pfizer secured a tariff exemption grace period after committing $70 billion to U.S. operations.
- AstraZeneca and Roche are undertaking multi-billion dollar U.S. expansions to retain market share.
- Eli Lilly and Johnson & Johnson are building new U.S. facilities and bolstering local production.
- Pharma companies are adopting direct-to-consumer strategies to minimize the impact of 100% drug tariffs.

**Companies:** Pfizer, AstraZeneca, Merck, Johnson & Johnson, Eli Lilly
**Countries:** United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/headlines/3896185-drugmakers-surge-us-investments-to-avoid-tariff-impact)

---

Canonical: https://newsio.io/n/1f2c5b6f-d41b-4a7d-a3fc-75fb57afaf5c/pfizer-astrazeneca-merck-and-others-are-capitalizing-on-exemptions-and-direct-co
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works